{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:25:36Z","timestamp":1787196336598,"version":"build-2736575974"},"reference-count":66,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"unspecified","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ministry of Health of British Columbia","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lillian and Thomas Embling Memorial Endowment Fund","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2026,7,25]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>We aimed to estimate the cardiovascular (CV) benefit of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) without a history of CV disease (CVD) (primary CVD prevention). We searched MEDLINE and the Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs) and Epistemonikos for systematic reviews (up to July 4, 2025). We included RCTs of patients with T2D comparing a GLP-1 RA to placebo using a CV or renal primary outcome. 11 drug manufacturer-funded trials (77 419 participants) were included. We used version 1 of the Cochrane risk of bias tool. Our primary analysis was the pooled estimate of the treatment effect in primary CVD prevention. Outcomes of interest were major adverse cardiovascular events (MACE, primary outcome), all-cause mortality, CV mortality, myocardial infarction, stroke, and serious adverse events (secondary outcomes). Only 26% of participants were primary CVD prevention patients. The pooled estimates of treatment effect for primary CVD prevention were not significant for the primary outcome, MACE (pooled HR 0.88, 95% CI 0.74 to 1.05, based on eight trials, n=16 672), and all secondary outcomes. The certainty of the evidence was rated as low due to trials\u2019 risk of bias and imprecision. Our review was limited to subgroup analyses of aggregated data from studies not powered for primary prevention alone. Current evidence is insufficient to establish CV benefits of GLP-1 RAs in T2D without a history of CVD, and dedicated primary prevention trials are needed.<\/jats:p>","DOI":"10.1136\/bmjdrc-2026-006225","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:02:51Z","timestamp":1787194971000},"page":"e006225","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like peptide-1 receptor agonists for primary cardiovascular disease prevention in type 2 diabetes, a systematic review"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct01018173","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01147250","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01179048","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01720446","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01144338","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02465515","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02692716","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01394952","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03496298","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01455896","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03819153","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03914326","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01147250","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01179048","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01720446","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01144338","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02465515","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02692716","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01394952","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03496298","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01455896","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03819153","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03914326","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05441267","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01018173","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5237-2581","authenticated-orcid":false,"given":"Guillaume","family":"Grenet","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Pharmacology, and Therapeutics, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada"},{"name":"Service hospitalo-universitaire de pharmacotoxicologie, Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raha","family":"Eskandari","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology, and Therapeutics, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology, and Therapeutics, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology, and Therapeutics, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M","family":"Salzwedel","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology, and Therapeutics, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balraj S","family":"Heran","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology, and Therapeutics, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0211-8654","authenticated-orcid":false,"given":"Anshula","family":"Ambasta","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology, and Therapeutics, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Bassett","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology, and Therapeutics, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8268-4092","authenticated-orcid":false,"given":"Wade","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology, and Therapeutics, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026081906551319000_14.4.e006225.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2026081906551319000_14.4.e006225.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"2026081906551319000_14.4.e006225.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"2026081906551319000_14.4.e006225.4","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"The Lancet"},{"key":"2026081906551319000_14.4.e006225.5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"The Lancet"},{"key":"2026081906551319000_14.4.e006225.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3024"},{"key":"2026081906551319000_14.4.e006225.7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"PubMed Central PMCID","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"2026081906551319000_14.4.e006225.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074068","article-title":"Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"381","author":"Shi","year":"2023","journal-title":"BMJ"},{"key":"2026081906551319000_14.4.e006225.9","doi-asserted-by":"publisher","DOI":"10.2337\/DCI22-0034"},{"key":"2026081906551319000_14.4.e006225.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2022.04.029"},{"key":"2026081906551319000_14.4.e006225.11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"2026081906551319000_14.4.e006225.12","doi-asserted-by":"crossref","unstructured":"Zhang Y , Liu C , Xu Y , et al . n.d. The management correlation between metabolic index, cardiovascular health, and diabetes combined with cardiovascular disease. Front Endocrinol 13. doi:10.3389\/fendo.2022.1036146","DOI":"10.3389\/fendo.2022.1036146"},{"key":"2026081906551319000_14.4.e006225.13","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s13300-021-01060-8","article-title":"Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review","volume":"12","author":"Artime","year":"2021","journal-title":"Diabetes Ther"},{"key":"2026081906551319000_14.4.e006225.14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","article-title":"CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries","volume":"20","author":"Mosenzon","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026081906551319000_14.4.e006225.15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.2640","article-title":"Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020","volume":"4","author":"Chen","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026081906551319000_14.4.e006225.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03273-3"},{"key":"2026081906551319000_14.4.e006225.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac810"},{"key":"2026081906551319000_14.4.e006225.18","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1177\/00033197231183229","article-title":"GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Patients With Versus Without Cardiovascular Disease: A Systematic Review, Meta-analysis, and Trial Sequential Analysis","volume":"75","author":"Kilickap","year":"2024","journal-title":"Angiology"},{"key":"2026081906551319000_14.4.e006225.19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2337\/dc23-0925","article-title":"A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes","volume":"47","author":"Karagiannis","year":"2024","journal-title":"Diabetes Care"},{"key":"2026081906551319000_14.4.e006225.20","doi-asserted-by":"crossref","DOI":"10.1017\/S2045796021000664","article-title":"The lack of statistical power of subgroup analyses in meta-analyses: a cautionary note","volume":"30","author":"Cuijpers","year":"2021","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2026081906551319000_14.4.e006225.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr077003"},{"key":"2026081906551319000_14.4.e006225.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01584-3"},{"key":"2026081906551319000_14.4.e006225.23","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad009"},{"key":"2026081906551319000_14.4.e006225.24","doi-asserted-by":"crossref","unstructured":"Higgins JPT , Green S , eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley-Blackwell, 2009:649.Available: https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/9780470712184","DOI":"10.1002\/9780470712184"},{"key":"2026081906551319000_14.4.e006225.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026081906551319000_14.4.e006225.26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12924"},{"key":"2026081906551319000_14.4.e006225.27","unstructured":"Chapter 2: Determining the Scope of the Review and the Questions It Will Address.Available: https:\/\/training.cochrane.org\/handbook\/current\/chapter-02"},{"key":"2026081906551319000_14.4.e006225.28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.12000","article-title":"Dipeptidyl peptidase\u20104 inhibitors and cardiovascular risk: a\u2009meta\u2010analysis of randomized clinical trials","volume":"15","author":"Monami","year":"2013","journal-title":"Diabetes Obesity Metabolism"},{"key":"2026081906551319000_14.4.e006225.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2019.10.011"},{"key":"2026081906551319000_14.4.e006225.30","article-title":"Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis","volume":"10","author":"Kanie","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2026081906551319000_14.4.e006225.31","unstructured":"Veritas Health Innovation . Covidence systematic review software. Melbourne, Australia,"},{"key":"2026081906551319000_14.4.e006225.32","doi-asserted-by":"crossref","unstructured":"Higgins JPT , Altman DG , G\u00f8tzsche PC , et al . The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 2011;343. doi:10.1136\/bmj.d5928","DOI":"10.1136\/bmj.d5928"},{"key":"2026081906551319000_14.4.e006225.33","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026081906551319000_14.4.e006225.34","article-title":"First-line diuretics versus other classes of antihypertensive drugs for hypertension","volume":"7","author":"Reinhart","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026081906551319000_14.4.e006225.35","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026081906551319000_14.4.e006225.36","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7411"},{"key":"2026081906551319000_14.4.e006225.37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","article-title":"R: A Language for Data Analysis and Graphics","volume":"5","author":"Ihaka","year":"1996","journal-title":"Journal of Computational and Graphical Statistics"},{"key":"2026081906551319000_14.4.e006225.38","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0315-7"},{"key":"2026081906551319000_14.4.e006225.39","unstructured":"Harrer M , Cuijpers P , Furukawa T , et al . dmetar: Companion R Package For The Guide \u201cDoing Meta-Analysis in R\u201d. 2019. Available: http:\/\/dmetar.protectlab.org\/"},{"key":"2026081906551319000_14.4.e006225.40","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05773-8"},{"key":"2026081906551319000_14.4.e006225.41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2026081906551319000_14.4.e006225.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225"},{"key":"2026081906551319000_14.4.e006225.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917"},{"key":"2026081906551319000_14.4.e006225.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"2026081906551319000_14.4.e006225.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108269"},{"key":"2026081906551319000_14.4.e006225.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347"},{"key":"2026081906551319000_14.4.e006225.47","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15058"},{"key":"2026081906551319000_14.4.e006225.48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069080","article-title":"Impact of polyethylene glycol loxenatide on cardiovascular outcomes in patients with type 2 diabetes: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3)","volume":"13","author":"Xie","year":"2023","journal-title":"BMJ Open"},{"key":"2026081906551319000_14.4.e006225.49","unstructured":"ClinicalTrials.gov . A study of cardiovascular events in diabetes plus. n.d. Available: https:\/\/clinicaltrials.gov\/study\/NCT05441267"},{"key":"2026081906551319000_14.4.e006225.50","unstructured":"ClinicalTrials.gov . A study of taspoglutide in patients with inadequately controlled diabetes mellitus type 2 and cardiovascular disease. n.d. Available: https:\/\/clinicaltrials.gov\/study\/NCT01018173"},{"key":"2026081906551319000_14.4.e006225.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"2026081906551319000_14.4.e006225.52","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"The Lancet"},{"key":"2026081906551319000_14.4.e006225.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505928"},{"key":"2026081906551319000_14.4.e006225.54","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.118.034516","article-title":"Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke","volume":"138","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"2026081906551319000_14.4.e006225.55","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0871-8"},{"key":"2026081906551319000_14.4.e006225.56","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/dom.14360","article-title":"Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide","volume":"23","author":"Verma","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026081906551319000_14.4.e006225.57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jclinepi.2018.12.015","article-title":"Rapid reviews may produce different results to systematic reviews: a meta-epidemiological study","volume":"109","author":"Marshall","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"2026081906551319000_14.4.e006225.58","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-024-08393-2","article-title":"Patient and public involvement and engagement in the ASCEND PLUS trial: reflections from the design of a streamlined and decentralised clinical trial","volume":"25","author":"El-Nayir","year":"2024","journal-title":"Trials"},{"key":"2026081906551319000_14.4.e006225.59","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j573","article-title":"Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?","volume":"PubMed PMID","author":"Fisher","year":"2017","journal-title":"BMJ"},{"key":"2026081906551319000_14.4.e006225.60","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.18219"},{"key":"2026081906551319000_14.4.e006225.61","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMc2407932","article-title":"Fair Allocation of GLP-1 and Dual GLP-1\u2013GIP Receptor Agonists","volume":"391","author":"Gong","year":"2024","journal-title":"N Engl J Med"},{"key":"2026081906551319000_14.4.e006225.62","doi-asserted-by":"crossref","first-page":"100197","DOI":"10.1016\/j.deman.2024.100197","article-title":"Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease","volume":"14","author":"Scheen","year":"2024","journal-title":"Diabetes Epidemiology and Management"},{"key":"2026081906551319000_14.4.e006225.63","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-022-01140-1","article-title":"Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom","volume":"22","author":"Brunetti","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"2026081906551319000_14.4.e006225.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.06.001"},{"key":"2026081906551319000_14.4.e006225.65","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0140-6736(24)01356-4","article-title":"International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches","volume":"404","author":"Dellgren","year":"2024","journal-title":"The Lancet"},{"key":"2026081906551319000_14.4.e006225.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.08.003"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2026-006225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:02:59Z","timestamp":1787194979000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2026-006225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":66,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjdrc-2026-006225"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2026-006225","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}